US 12,227,744 B2
Compositions and methods for inhibiting expression of transthyretin
Dinah Wen-Yee Sah, Boston, MA (US); Gregory Hinkle, Plymouth, MA (US); Rene Alvarez, Boxborough, MA (US); Stuart Milstein, Arlington, MA (US); and Qingmin Chen, Lincoln, MA (US)
Assigned to Alnylam Pharmaceuticals, Inc., Cambridge, MA (US)
Filed by Alnylam Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Apr. 15, 2022, as Appl. No. 17/721,704.
Application 17/721,704 is a continuation of application No. 17/475,142, filed on Sep. 14, 2021, abandoned.
Application 17/475,142 is a continuation of application No. 17/360,849, filed on Jun. 28, 2021, abandoned.
Application 17/360,849 is a continuation of application No. 17/234,657, filed on Apr. 19, 2021, abandoned.
Application 17/234,657 is a continuation of application No. 17/102,351, filed on Nov. 23, 2020, abandoned.
Application 17/102,351 is a continuation of application No. 16/751,026, filed on Jan. 23, 2020, abandoned.
Application 16/751,026 is a continuation of application No. 16/276,541, filed on Feb. 14, 2019, abandoned.
Application 16/276,541 is a continuation of application No. 15/380,571, filed on Dec. 15, 2016, granted, now 10,240,152, issued on Mar. 26, 2019.
Application 15/380,571 is a continuation of application No. 14/965,825, filed on Dec. 10, 2015, abandoned.
Application 14/965,825 is a continuation of application No. 14/220,829, filed on Mar. 20, 2014, granted, now 9,234,196, issued on Jan. 12, 2016.
Application 14/220,829 is a continuation of application No. 13/410,262, filed on Mar. 1, 2012, granted, now 8,741,866, issued on Jun. 3, 2014.
Application 13/410,262 is a continuation of application No. 12/582,669, filed on Oct. 20, 2009, granted, now 8,168,775, issued on May 1, 2012.
Claims priority of provisional application 61/244,794, filed on Sep. 22, 2009.
Claims priority of provisional application 61/242,783, filed on Sep. 15, 2009.
Claims priority of provisional application 61/185,545, filed on Jun. 9, 2009.
Claims priority of provisional application 61/156,670, filed on Mar. 2, 2009.
Claims priority of provisional application 61/115,738, filed on Nov. 18, 2008.
Claims priority of provisional application 61/106,956, filed on Oct. 20, 2008.
Prior Publication US 2023/0257740 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/02 (2006.01); A61K 9/00 (2006.01); A61K 31/713 (2006.01); C07F 9/6533 (2006.01); C07H 21/04 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01)
CPC C12N 15/113 (2013.01) [A61K 9/0019 (2013.01); A61K 31/713 (2013.01); C07F 9/6533 (2013.01); C07H 21/04 (2013.01); C12N 15/111 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/335 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/30 (2013.01); C12N 2320/32 (2013.01)] 11 Claims
 
1. A pharmaceutical composition comprising a double-stranded ribonucleic acid (dsRNA) for inhibiting expression of transthyretin (TTR), wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein each strand of the dsRNA is 19, 20, 21, 22, 23, or 24 nucleotides in length; wherein the antisense strand comprises 15 or more contiguous nucleotides of SEQ ID NO: 170, SEQ ID NO:450, SEQ ID NO:730, or SEQ ID NO: 1010; and a lipid formulation comprising a cationic lipid, a non-cationic lipid, and a polyethyleneglycol (PEG)-lipid.